Omnicell (NASDAQ:OMCL) Upgraded at StockNews.com

Omnicell (NASDAQ:OMCL) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Other equities analysts have also issued research reports about the company. JPMorgan Chase & Co. cut their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research note on Thursday, March 20th. Wells Fargo & Company dropped their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Finally, Benchmark reaffirmed a “buy” rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Performance

NASDAQ:OMCL traded down $0.26 during trading hours on Tuesday, reaching $31.35. The company had a trading volume of 498,107 shares, compared to its average volume of 529,895. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.75. The business’s 50 day moving average price is $35.92 and its 200-day moving average price is $41.52. The firm has a market cap of $1.47 billion, a PE ratio of 116.12, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Research analysts forecast that Omnicell will post 1.09 EPS for the current year.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently added to or reduced their stakes in the business. Lazard Asset Management LLC grew its stake in Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after purchasing an additional 737,536 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after buying an additional 699,925 shares during the period. Toronto Dominion Bank acquired a new position in shares of Omnicell during the fourth quarter worth about $30,637,000. Dimensional Fund Advisors LP raised its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock valued at $73,127,000 after purchasing an additional 394,820 shares in the last quarter. Finally, Victory Capital Management Inc. raised its stake in Omnicell by 32.9% in the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after buying an additional 377,883 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.